Octocog alfa sucrose formulation - Bayer HealthCare

Drug Profile

Octocog alfa sucrose formulation - Bayer HealthCare

Alternative Names: BAY 81-8973; BAY-14-2222; Factor VIII sucrose formulation - Bayer; Helixate FS; Helixate NexGen; Iblias; Kogenate Bayer; Kogenate FS; Kogenate PF; Kogenate SF; Kovaltry; rFVIII FS

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; CSL Behring
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 24 Jul 2018 Registered for Haemophilia A (In adolescents, Prevention, In adults) in China (IV)
  • 24 Jul 2018 Registered for Haemophilia A (In children, In adults) in China (IV)
  • 29 Jun 2016 Launched for Haemophilia A in Japan (IV) before June 2016 (PMDA website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top